Skip to main content

CORRECTION article

Front. Immunol., 19 December 2023
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1352909
This article is part of the Research Topic Vector-based Cancer Immunotherapy View all 10 articles

Corrigendum: Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma

Mingming Hu,&#x;Mingming Hu1,2†XuLiang Liao,&#x;XuLiang Liao1,2†Yi Tao,&#x;Yi Tao1,2†Yaohui Chen,*Yaohui Chen1,3*
  • 1Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China
  • 2Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China
  • 3Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China

A Corrigendum on
Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma

By Hu M, Liao X, Tao Y and Chen Y (2023) Front. Immunol. 14:1285113. doi: 10.3389/fimmu.2023.1285113

In the published article, there was an error in the Funding statement. We overlooked the fund that supported this article.

The correct Funding statement appears below:

“This work was supported by the 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (Y.C., ZYJC21015).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: oncolytic viruses, cancer therapy, recurrent gliomas, oncolytic herpes simplex virus, adenovirus therapy

Citation: Hu M, Liao X, Tao Y and Chen Y (2023) Corrigendum: Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma. Front. Immunol. 14:1352909. doi: 10.3389/fimmu.2023.1352909

Received: 09 December 2023; Accepted: 12 December 2023;
Published: 19 December 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Hu, Liao, Tao and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yaohui Chen, mcb.chenyaohui@gmail.com

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.